Kelly LM, Gilliland DG (2002) Genetics of myeloid leukemias. Annu Rev Genomics Hum Genet 3:179–198

Article  CAS  PubMed  Google Scholar 

Almeida AM, Ramos F (2016) Acute myeloid leukemia in the older adults. Leuk Res Rep 6:1–7

PubMed  PubMed Central  Google Scholar 

Winer ES, Stone RM (2019) Novel therapy in acute myeloid leukemia (AML): moving toward targeted approaches. Ther Adv Hematol 10:2040620719860645

Article  CAS  PubMed  PubMed Central  Google Scholar 

Cluzeau T, Sebert M, Rahmé R et al (2021) Eprenetapopt plus Azacitidine in TP53-mutated myelodysplastic syndromes and acute myeloid leukemia: a phase II study by the Groupe Francophone des Myélodysplasies (GFM). J Clin Oncol 39(14):1575–1583

Article  CAS  PubMed  PubMed Central  Google Scholar 

Granfeldt Østgård LS, Medeiros BC, Sengeløv H et al (2015) Epidemiology and clinical significance of secondary and therapy-related acute myeloid leukemia: a national population-based cohort study. J Clin Oncol 33(31):3641–3649

Article  PubMed  Google Scholar 

Leone G, Mele L, Pulsoni A, Equitani F, Pagano L (1999) The incidence of secondary leukemias. Haematologica 84(10):937–945

CAS  PubMed  Google Scholar 

Miesner M, Haferlach C, Bacher U et al (2010) Multilineage dysplasia (MLD) in acute myeloid leukemia (AML) correlates with MDS-related cytogenetic abnormalities and a prior history of MDS or MDS/MPN but has no independent prognostic relevance: a comparison of 408 cases classified as “AML not otherwise specified” (AML-NOS) or “AML with myelodysplasia-related changes” (AML-MRC). Blood 116(15):2742–2751

Article  CAS  PubMed  Google Scholar 

Grimwade D, Hills RK, Moorman AV et al (2010) Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood 116(3):354–365

Article  CAS  PubMed  Google Scholar 

Arber DA, Orazi A, Hasserjian R et al (2016) The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 127(20):2391–2405

Article  CAS  PubMed  Google Scholar 

Fianchi L, Pagano L, Piciocchi A et al (2015) Characteristics and outcome of therapy-related myeloid neoplasms: report from the Italian network on secondary leukemias. Am J Hematol 90(5):E80–E85

Article  CAS  PubMed  Google Scholar 

Samra B, Richard-Carpentier G, Kadia TM et al (2020) Characteristics and outcomes of patients with therapy-related acute myeloid leukemia with normal karyotype. Blood Cancer J 10(5):47

Article  PubMed  PubMed Central  Google Scholar 

Huntington SF, Ingham MP, Okonkwo L, Singh A, Wang R, Ammann EM (2022) Treatment patterns, economic burden, and overall survival in US Medicare advantage beneficiaries newly diagnosed with acute myeloid leukemia (AML) in 2015–2020. Leuk Lymphoma 63(5):1180–1190

Article  CAS  PubMed  Google Scholar 

Uras IZ, Sexl V, Kollmann K (2020) CDK6 inhibition: a novel approach in AML management. Int J Mol Sci 21(7):2528

Article  CAS  PubMed  PubMed Central  Google Scholar 

Malumbres M, Barbacid M (2009) Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 9:153–166

Article  CAS  PubMed  Google Scholar 

Leonard JP, LaCasce AS, Smith MR et al (2012) Selective CDK4/6 inhibition with tumor responses by PD0332991 in patients with mantle cell lymphoma. Blood 119(20):4597–4607

Article  CAS  PubMed  Google Scholar 

Geoerger B, Bourdeaut F, DuBois SG et al (2017) A phase I study of the CDK4/6 inhibitor Ribociclib (LEE011) in pediatric patients with malignant rhabdoid tumors, neuroblastoma, and other solid tumors. Clin Cancer Res 23(10):2433–2441

Article  CAS  PubMed  Google Scholar 

Patnaik A, Rosen LS, Tolaney SM et al (2016) Efficacy and safety of Abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov 6(7):740–753

Article  CAS  PubMed  Google Scholar 

Dickson MA, Schwartz GK, Keohan ML et al (2016) Progression-free survival among patients with well-differentiated or dedifferentiated liposarcoma treated with CDK4 inhibitor palbociclib: a phase 2 clinical trial. JAMA Oncol 2(7):937–940

Article  PubMed  PubMed Central  Google Scholar 

Fröhling S, Agrawal M, Jahn N et al (2016) CDK4/6 inhibitor palbociclib for treatment of KMT2A-rearranged acute myeloid leukemia: interim analysis of the AMLSG 23–14 trial. Blood 128:1608

Article  Google Scholar 

Kadia TM, Konopleva MY, Garcia-Manero G et al (2018) Phase I study of Palbociclib alone and in combination in patients with relapsed and refractory (R/R) leukemias. Blood 132(Suppl S1):4057

Article  Google Scholar 

Wang A, Fang M, Jiang H et al (2022) Palbociclib promotes the antitumor activity of Venetoclax plus Azacitidine against acute myeloid leukemia. Biomed Pharmacother 153:113527

Article  CAS  PubMed  Google Scholar 

Schmoellerl J, Barbosa IAM, Eder T et al (2020) CDK6 is an essential direct target of NUP98 fusion proteins in acute myeloid leukemia. Blood 136(4):387–400

Article  PubMed  Google Scholar